TPI Attends CPhI to Facilitate Azithromycin API Export Business - WFSB 3 Connecticut

TPI Attends CPhI to Facilitate Azithromycin API Export Business

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Tianyin Pharmaceutical Co., Inc.

CHENGDU, China, June 29, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) attended 2014 China Pharmaceutical International Conference and Exhibit (CPhI China: http://www.cphi-china.cn/) held at Shanghai from June 26th till 28th, 2014 to facilitate the business development of its API division, Jiangchuan Macrolide Facility (JCM).

During the conference period, new API orders were initiated and the details of the export contracts were negotiated on a series of Azithromycin APIs including Azithromycin Amine (Azi Amine), in addition to JCM's projected monthly orders of 5-8 tons per month for international export. TPI will provide further updates until the details of these orders are substantiated.

About CPhI China

CPhI China (http://www.cphi.com/china/home/ ) is the leading international event in China for pharmaceutical API sales and marketing including plant and herbal extracts business, biochemical API sales, manufacturing and laboratory equipment and supplies along with information/consulting platforms that facilitate companies' export business and international compliances including EU and US certifications. There were more than 2,500 exhibitors with 140,000 square meters of total exhibition areas at the event and over 30,000 visitors from 140 countries. At Shanghai International Conference Center at Pudong, Shanghai, CPhI China is co-located with P-MEC, ICSE, LABWorld, InnoPack, BioPh and features areas for Natural Extracts and EP CLean Tech. CPhI China is also co-located with Food ingredients dietary supplements Asia-China exhibit, Health ingredients & Natural ingredients (Fi Asia-China, Hi & Ni) and Natural & Nutraceutical products China (NPC) conferences.

About Azithromycin and its intermediates

Azithromycin (Azi) is a macrolide antibiotic related to erythromycin. It is used primarily to treat various bacterial infections caused by respiratory pathogens, such as Aerobic gram-positive microorganisms and Aerobic gram-negative microorganisms. Azi prevents bacterial cells from manufacturing specific proteins necessary for their survival. Azi is rapidly absorbed and is widely distributed to tissues and becomes concentrated in cells. Peak plasma concentrations are achieved within 2 to 3 hours. Azithromycin Amine (Azi Amine) is a close intermediate of Azi and enjoys a competitive pricing trend amongst various derivatives of Azi related products. At JCM, following a series of tests on quality, purity, intermediates contents, stereochemistry, stability in comparison with the international standards of Azi APIs, JCM currently is processing monthly orders for manufacturing Azi Amine at a competitive international price.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit:  http://www.tianyinpharma.com

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia

Tel:  +86-28-8551-6696 (Chengdu, China)

Address:
Tianyin Pharmaceutical Inc.
23rd Floor, Unionsun Yangkuo Plaza     
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
Eyewitness News 3
Powered by WorldNow CNN
All content © 2014, WFSB; Hartford, CT. (A Meredith Corporation Station) and WorldNow. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.